Presentations on sickle cell disease (SCD) at the European Hematology Association (EHA) Virtual Congress 2021 spotlighted disease-causing mechanisms, hallmark symptoms, and commonly associated complications. Analysis and discussion focused on traditional therapies such as blood transfusions, haematopoietic stem cell transplantation, and hydroxyurea, whilst also highlighting the promise of a new generation of treatments: gene therapies. Gene addition, gene editing, and gene silencing, though all in the early stages of development, hold exciting potential for patients with SCD.
Latest articles
All articles
4 Mins
10th
December
EAHAD 2025 Congress Presidential Interview: Flora Peyvandi
I love to do medicine, and I always wanted to do internal medicine-haematology, because I thought haematology was just facing up to blood…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
9 Mins
14th
August
Recent Advancements in wAIHA
AIHA is an acquired, heterogeneous group of rare diseases with a prevalence of 17 per 100,000.1 This group includes wAIHA…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
3 Mins
25th
July
Filgrastim Prophylaxis for Neutropenia in Myelodysplasia Pre-Surgery: Case Report
Myelodysplastic syndromes are a group of disorders that affect the bone marrow, subsequently affecting the growth and relative…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.